Recombinant Tissue-type Plasminogen Activator Thrombolytic Therapy of Acute Cerebral Infarction and Safety
Author：ZHANG Ming-zhi
affiliation：Department of Neurology, Luohu People's Hospital of Shenzhen, Shenzhen 518000, Guangdong Province,China
PDFAbstract
Objective To observe the clinical application of recombinant tissue plasminogen activator (rt-PA) clinical efficacy and safety of intravenous thrombolytic therapy for acute cerebral infarction. Methods 66 cases of patients with acute cerebral infarction in July 2013 ~2015 year in July were treated in our hospital, were randomly divided into control group and observation group of 33 cases and the control group were treated with Sodium Ozagrel and Sodium Chloride Injection, the observation group was treated with rt-PA, to observe the clinical efficacy and adverse reactions of the two groups after treatment were observed. Results The clinical treatment of two groups of patients after total effective observation group was significantly higher (P<0.05), whereas no significant difference in safety (P>0.05). Conclusion The clinical application of rt-PA thrombolytic therapy of acute cerebral infarction can significantly improve treatment efficiency and safety can be applied in clinical practice.
【Keyword】Recombinant Tissue-type Plasminogen Activator; Thrombolytic Therapy; Acute Cerebral Infarction
【Chart number】R651.1
【Document Identification Number】A
【DOI】10.3969/j.issn.1009-3257.2016.04.008
Journal of Rare Diseases
th23Volume， th 5 Issue
2019Year11Month
Related articles
Editor email：（1）中国CT和MRI杂志：ctmri@vip.163.com；（2）罕少疾病杂志：hs1999@vip.163.com
Contact number：0755-83695203
Our address：
English
简体中文
logged in
Wechat
TouTiao